FDA Overhauls 'Dear Doctor' Guidance On Drug Risks
The U.S. Food and Drug Administration on Wednesday finalized guidance on how drugmakers should warn physicians of newly discovered risks, eliminating expectations for tracking the impact of "dear doctor" letters but...To view the full article, register now.
Already a subscriber? Click here to view full article